IL111991A - Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent - Google Patents

Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent

Info

Publication number: IL111991A
Authority: IL; Israel
Prior art keywords: pharmaceutical composition; organic solvent; hiv protease; protease inhibitors; liquid pharmaceutical
Prior art date: 1994-01-28

Application number

IL11199194A

Other languages

English (en)

Other versions

IL111991A0 (en

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-01-28

Filing date

1994-12-15

Publication date

2000-07-26

1994-12-15 Application filed by Abbott Lab filed Critical Abbott Lab

1995-03-15 Publication of IL111991A0 publication Critical patent/IL111991A0/xx

2000-07-26 Publication of IL111991A publication Critical patent/IL111991A/xx

Links

239000003960 organic solvent Substances 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
239000004030 hiv protease inhibitor Substances 0.000 title 1
239000007788 liquid Substances 0.000 title 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
239000002202 Polyethylene glycol Substances 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
229920001223 polyethylene glycol Polymers 0.000 abstract 2
239000002904 solvent Substances 0.000 abstract 2
108010010369 HIV Protease Proteins 0.000 abstract 1
239000004359 castor oil Substances 0.000 abstract 1
235000019438 castor oil Nutrition 0.000 abstract 1
239000003240 coconut oil Substances 0.000 abstract 1
235000019864 coconut oil Nutrition 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 abstract 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
229920000053 polysorbate 80 Polymers 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL11199194A 1994-01-28 1994-12-15 Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent IL111991A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US18902194A	1994-01-28	1994-01-28
US28323994A	1994-07-29	1994-07-29

Publications (2)

Publication Number	Publication Date
IL111991A0 IL111991A0 (en)	1995-03-15
IL111991A true IL111991A (en)	2000-07-26

Family

ID=26884695

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11199194A IL111991A (en)	1994-01-28	1994-12-15	Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent

Country Status (13)

Country	Link
US (1)	US5484801A (da)
EP (1)	EP0732923B1 (da)
JP (1)	JP4353542B2 (da)
KR (1)	KR100360963B1 (da)
AT (1)	ATE210441T1 (da)
AU (1)	AU700942B2 (da)
CA (1)	CA2178632C (da)
DE (1)	DE69524567T2 (da)
DK (1)	DK0732923T3 (da)
ES (1)	ES2169121T3 (da)
IL (1)	IL111991A (da)
PT (1)	PT732923E (da)
WO (1)	WO1995020384A1 (da)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2170020C (en) *	1992-12-29	2005-08-02	Dale J. Kempf	Retroviral protease inhibiting compounds
IL110752A (en) *	1993-09-13	2000-07-26	Abbott Lab	Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
WO1996003113A1 (en) *	1994-07-22	1996-02-08	G.D. Searle & Co.	Self-emulsifying drug delivery system
US5705524A (en) *	1994-11-04	1998-01-06	Gilead Sciences, Inc.	Thiepane compounds
US6034118A (en) *	1994-11-04	2000-03-07	Gilead Sciences, Inc.	Thiepane compounds
US6037157A (en)	1995-06-29	2000-03-14	Abbott Laboratories	Method for improving pharmacokinetics
AU7508196A (en)	1995-11-13	1997-06-05	Gerard Voerman	Anti-viral isolates obtainable from leeches
US5914332A (en)	1995-12-13	1999-06-22	Abbott Laboratories	Retroviral protease inhibiting compounds
US6730679B1 (en)	1996-03-22	2004-05-04	Smithkline Beecham Corporation	Pharmaceutical formulations
AU3146997A (en) *	1996-06-03	1998-01-05	Merck & Co., Inc.	Pediatric formulation for hiv protease inhibitors
KR100509388B1 (ko)	1996-10-18	2005-08-23	버텍스 파마슈티칼스 인코포레이티드	세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제
US6232333B1 (en)	1996-11-21	2001-05-15	Abbott Laboratories	Pharmaceutical composition
ZA9710071B (en) *	1996-11-21	1998-05-25	Abbott Lab	Pharmaceutical composition.
MY121765A (en) *	1998-07-20	2006-02-28	Abbott Lab	Polymorph of ritonavir
US6894171B1 (en) *	1998-07-20	2005-05-17	Abbott Laboratories	Polymorph of a pharmaceutical
CA2351516A1 (en) *	1998-11-18	2000-05-25	Valery Alakhov	Copolymer compositions for treating viral infections
US6638522B1 (en)	1998-12-11	2003-10-28	Pharmasolutions, Inc.	Microemulsion concentrate composition of cyclosporin
BE1012622A3 (fr) *	1999-04-21	2001-01-09	Solvay	Procede pour la separation d'enantiomeres et reactif enantiopur.
US6057289A (en) *	1999-04-30	2000-05-02	Pharmasolutions, Inc.	Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
TR200103488T2 (tr) †	1999-06-04	2002-04-22	Abbott Laboratories	Geliştirilmiş farmasötik formülasyonlar.
US7141593B1 (en)	1999-06-04	2006-11-28	Abbott Laboratories	Pharmaceutical formulations
US6589962B1 (en)	1999-07-20	2003-07-08	Merck & Co., Inc.	Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
AU6109500A (en) *	1999-07-20	2001-02-05	Merck & Co., Inc.	Alpha-hydroxy-gamma-(((carbocyclic-or heterocyclic-substituted)amino)carbonyl)alkanamide derivatives and uses thereof
EP1175205B1 (en)	1999-11-12	2006-06-14	Abbott Laboratories	Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US7364752B1 (en)	1999-11-12	2008-04-29	Abbott Laboratories	Solid dispersion pharamaceutical formulations
US6642237B1 (en)	1999-11-24	2003-11-04	Merck & Co., Inc.	Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof
GB0000313D0 (en) *	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
TR201809435T4 (tr) *	2000-01-19	2018-07-23	Abbvie Inc	Geliştirilmiş farmasötik formülasyonlar.
US7138538B2 (en) *	2000-04-14	2006-11-21	Solvay (Societe Anonyme)	Process for the separation of enantiomers and enantiopure reagent
SV2003000617A (es)	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
MXPA03001952A (es) *	2000-09-05	2003-09-10	Abbott Lab	Sistemas saborizantes para composiciones farmaceuticas y metodos para hacer dichas composiciones.
US6911214B2 (en) *	2000-09-05	2005-06-28	Abbott Laboratories	Flavoring systems for pharmaceutical compositions and methods of making such compositions
DE60132103T2 (de) *	2000-10-31	2008-04-17	Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield	Perorale, selbst-emulgierende darreichungsformen von pyranon-proteaseinhibitoren
CA2432527A1 (en) *	2000-12-22	2002-07-04	Takeda Chemical Industries, Ltd.	Medicinal compositions for oral use
WO2002078669A1 (fr) *	2001-03-30	2002-10-10	Takeda Chemical Industries, Ltd.	Solutions medicinales
US20030138483A1 (en) *	2001-05-25	2003-07-24	Sergio Petriconi	Soft elastic capsules and compositions thereof
US20030191121A1 (en) *	2001-08-09	2003-10-09	Miller Ross A.	Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
EP2316468A1 (en)	2002-02-22	2011-05-04	Shire LLC	Delivery system and methods for protecting and administering dextroamphetamine
US20040067216A1 (en) *	2002-02-22	2004-04-08	Karki Shyam B.	Hiv protease inhibitors supported on cation exchange resins for oral administration
WO2004050068A1 (en)	2002-11-29	2004-06-17	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
WO2004054586A1 (en) *	2002-12-16	2004-07-01	Boehringer Ingelheim International Gmbh	Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
US8377952B2 (en)	2003-08-28	2013-02-19	Abbott Laboratories	Solid pharmaceutical dosage formulation
US8025899B2 (en)	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
TWI359147B (en) *	2003-09-05	2012-03-01	Vertex Pharma	Inhibitors of serine proteases, particularly hcv n
EP1670415A4 (en) *	2003-09-12	2007-12-05	Vertex Pharma	ANIMAL MODEL FOR STUDYING PROTEASES ACTIVITY AND HEPATIC DISORDERS
WO2005037860A2 (en)	2003-10-10	2005-04-28	Vertex Pharmaceuticals Incoporated	Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
KR20060120166A (ko) *	2003-10-27	2006-11-24	버텍스 파마슈티칼스 인코포레이티드	Ｈｃｖｎｓ３－ｎｓ４ａ 단백질분해효소 저항성 돌연변이
EP1944042A1 (en)	2003-10-27	2008-07-16	Vertex Pharmceuticals Incorporated	Combinations for HCV treatment
CN1938332B (zh)	2004-02-04	2011-10-19	沃泰克斯药物股份有限公司	丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
RU2007116265A (ru)	2004-10-01	2008-11-10	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Ингибирование протеазы ns3-ns4a вируса hcv
TW201424733A (zh)	2004-10-29	2014-07-01	Vertex Pharma	劑量型式
WO2006090270A1 (en) *	2005-02-28	2006-08-31	Ranbaxy Laboratories Limited	Acid addition salt of 2-isopropyl-4-(((n-methyl)amino)methyl)thiazole and its?use in the preparation of ritonavir
PE20070211A1 (es)	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
WO2007014922A1 (en) *	2005-07-29	2007-02-08	Tibotec Pharmaceuticals Ltd.	Macrocyclic inhibitors of hepatitis c virus
JP5230416B2 (ja)	2005-07-29	2013-07-10	テイボテク・フアーマシユーチカルズ	Ｃ型肝炎ウイルスの大員環状阻害剤
CN101273042B (zh) *	2005-07-29	2013-11-06	泰博特克药品有限公司	丙型肝炎病毒的大环抑制剂
PE20070210A1 (es)	2005-07-29	2007-04-16	Tibotec Pharm Ltd	Compuestos macrociclicos como inhibidores del virus de hepatitis c
CA2617099C (en) *	2005-07-29	2014-03-25	Tibotec Pharmaceuticals Ltd.	Macrocyclic inhibitors of hepatitis c virus
ES2373685T3 (es) *	2005-07-29	2012-02-07	Tibotec Pharmaceuticals	Inhibidores macrocíclicos del virus de la hepatitis c.
JO2768B1 (en)	2005-07-29	2014-03-15	تيبوتيك فارماسيوتيكالز ليمتد	Large cyclic inhibitors of hepatitis C virus
KR20080033481A (ko) *	2005-08-02	2008-04-16	버텍스 파마슈티칼스 인코포레이티드	세린 프로테아제의 억제제
AR055395A1 (es) *	2005-08-26	2007-08-22	Vertex Pharma	Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en)	2005-08-26	2011-06-21	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases
EP2392589A3 (en)	2005-11-11	2012-06-20	Vertex Pharmaceuticals Incorporated	Hepatitis C virus variants
US7705138B2 (en)	2005-11-11	2010-04-27	Vertex Pharmaceuticals Incorporated	Hepatitis C virus variants
EP1991229A2 (en)	2006-02-27	2008-11-19	Vertex Pharmaceuticals Incorporated	Co-crystals and pharmaceutical compositions comprising the same
EP1993994A2 (en) *	2006-03-16	2008-11-26	Vertex Pharmceuticals Incorporated	Deuterated hepatitis c protease inhibitors
CA2661338C (en) *	2006-11-17	2015-05-12	Tibotec Pharmaceuticals Ltd.	Macrocyclic inhibitors of hepatitis c virus
BRPI0807087A2 (pt) *	2007-02-08	2014-06-10	Tibotec Pharm Ltd	Inibidores de hcv macrocíclicos substituídos de pirimidina
JP2010519329A (ja) *	2007-02-27	2010-06-03	バーテックスファーマシューティカルズインコーポレイテッド	セリンプロテアーゼ阻害剤
DK2114924T3 (da) *	2007-02-27	2012-04-10	Vertex Pharma	Co-krystaller og farmaceutiske sammensætninger omfattende disse
EP2142215B1 (en)	2007-05-04	2012-03-07	Vertex Pharmceuticals Incorporated	Combination therapy for the treatment of hcv infection
CN101835774B (zh) *	2007-08-30	2014-09-17	弗特克斯药品有限公司	共晶体和包含该共晶体的药物组合物
US20100093811A1 (en) *	2007-09-25	2010-04-15	Coburn Craig A	Hiv protease inhibitors
NZ584968A (en) *	2007-10-29	2012-11-30	Cipla Ltd	Novel antiretroviral combination comprising ritonavir and atazanavir
GT200800303A (es) *	2007-12-24	2009-09-18		Combinacion anti-retroviral
AR072428A1 (es) *	2008-07-01	2010-08-25	Medivir Ab	Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos.
WO2010093843A2 (en)	2009-02-12	2010-08-19	Vertex Pharmaceuticals Incorporated	Hcv combination therapies
PL2421527T3 (pl)	2009-04-25	2018-10-31	F.Hoffmann-La Roche Ag	Sposoby poprawy właściwości farmakokinetycznych
EP2435037B1 (en)	2009-05-27	2014-11-12	Merck Sharp & Dohme Corp.	Hiv protease inhibitors
RU2012136824A (ru)	2010-01-29	2014-03-10	Вертекс Фармасьютикалз Инкорпорейтед	Способы лечения вирусной инфекции гепатита с
WO2012010942A2 (en)	2010-07-22	2012-01-26	Lupin Limited	Novel pharmaceutical composition(s) of hiv protease inhibitor(s)
EP2632895B1 (en)	2010-10-28	2018-10-03	Merck Canada Inc.	Hiv protease inhibitors
WO2012109646A1 (en)	2011-02-11	2012-08-16	Vertex Pharmaceuticals Incorporated	Treatment of hcv in hiv infection patients
CA2837266A1 (en)	2011-05-27	2012-12-06	Hetero Research Foundation	Amorphous ritonavir co-precipitated
EP2771332B1 (en)	2011-10-26	2016-06-29	Merck Canada Inc.	Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS
CA2882831A1 (en)	2012-09-11	2014-03-20	Merck Sharp & Dohme Corp.	Hiv protease inhibitors
WO2015013835A1 (en)	2013-07-31	2015-02-05	Merck Sharp & Dohme Corp.	Piperazine derivatives as hiv protease inhibitors
UA117375C2 (uk)	2013-09-04	2018-07-25	Медівір Аб	Інгібітори полімерази hcv
WO2015056213A1 (en)	2013-10-17	2015-04-23	Medivir Ab	Hcv polymerase inhibitors
WO2015095265A1 (en)	2013-12-19	2015-06-25	Merck Sharp & Dohme Corp.	Hiv protease inhibitors
US9834526B2 (en)	2013-12-19	2017-12-05	Merck Sharp & Dohme Corp.	HIV protease inhibitors
EP3113780B1 (en)	2014-03-06	2019-08-14	Merck Sharp & Dohme Corp.	Hiv protease inhibitors
WO2015138220A1 (en)	2014-03-10	2015-09-17	Merck Sharp & Dohme Corp.	Piperazine derivatives as hiv protease inhibitors
US9738664B2 (en)	2014-10-29	2017-08-22	Wisconsin Alumni Research Foundation	Boronic acid inhibitors of HIV protease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5086165A (en) *	1989-03-08	1992-02-04	Washington University	Inhibitors of retroviral protease with a ketomethylene isosteric replaced amide bond
US5342922A (en) *	1989-03-08	1994-08-30	Washington University	Inhibitors of retroviral protease
US5256677A (en) *	1989-05-23	1993-10-26	Abbott Laboratories	Retroviral protease inhibiting compounds
US5354866A (en) *	1989-05-23	1994-10-11	Abbott Laboratories	Retroviral protease inhibiting compounds
US5164300A (en) *	1989-12-28	1992-11-17	Washington University	Method for determining activity of retroviral protease
JPH05508855A (ja) *	1990-07-06	1993-12-09	スミスクライン・ビーチャム・コーポレイション	レトロウイルスプロテアーゼ阻害剤
US5171662A (en) *	1990-09-13	1992-12-15	The Upjohn Company	Method of detecting HIV protease activity
US5183826A (en) *	1990-09-25	1993-02-02	Merck & Co., Inc.	Antiviral agent
IE20010533A1 (en) *	1990-11-20	2003-03-05	Abbott Lab	Intermediates for preparing retroviral protease inhibiting compounds
EP0575500A4 (en) *	1991-03-08	1994-06-01	Smithkline Beecham Corp	Hiv protease inhibitors
EP0532466A3 (en) *	1991-09-12	1993-06-16	Ciba-Geigy Ag	Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
US5250563A (en) *	1991-09-25	1993-10-05	Merck & Co., Inc.	Inhibitors of HIV protease
US5296604A (en) *	1992-05-15	1994-03-22	Miles Inc.	Proline derivatives and compositions for their use as inhibitors of HIV protease
CA2170020C (en) *	1992-12-29	2005-08-02	Dale J. Kempf	Retroviral protease inhibiting compounds

1994
- 1994-12-15 IL IL11199194A patent/IL111991A/xx not_active IP Right Cessation
1995
- 1995-01-03 ES ES95906790T patent/ES2169121T3/es not_active Expired - Lifetime
- 1995-01-03 EP EP95906790A patent/EP0732923B1/en not_active Expired - Lifetime
- 1995-01-03 AT AT95906790T patent/ATE210441T1/de active
- 1995-01-03 DK DK95906790T patent/DK0732923T3/da active
- 1995-01-03 JP JP52005995A patent/JP4353542B2/ja not_active Expired - Lifetime
- 1995-01-03 AU AU15248/95A patent/AU700942B2/en not_active Expired
- 1995-01-03 KR KR1019960704162A patent/KR100360963B1/ko not_active Expired - Lifetime
- 1995-01-03 CA CA002178632A patent/CA2178632C/en not_active Expired - Lifetime
- 1995-01-03 PT PT95906790T patent/PT732923E/pt unknown
- 1995-01-03 WO PCT/US1995/000232 patent/WO1995020384A1/en not_active Ceased
- 1995-01-03 DE DE69524567T patent/DE69524567T2/de not_active Expired - Lifetime
- 1995-05-12 US US08/440,277 patent/US5484801A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE69524567T2 (de)	2002-09-05
EP0732923B1 (en)	2001-12-12
IL111991A0 (en)	1995-03-15
US5484801A (en)	1996-01-16
DE69524567D1 (de)	2002-01-24
AU700942B2 (en)	1999-01-14
WO1995020384A1 (en)	1995-08-03
HK1011609A1 (en)	1999-07-16
EP0732923A1 (en)	1996-09-25
CA2178632A1 (en)	1995-08-03
JP4353542B2 (ja)	2009-10-28
CA2178632C (en)	2006-04-11
KR100360963B1 (ko)	2003-02-11
AU1524895A (en)	1995-08-15
ATE210441T1 (de)	2001-12-15
DK0732923T3 (da)	2002-04-08
ES2169121T3 (es)	2002-07-01
PT732923E (pt)	2002-05-31

Legal Events

Date	Code	Title
2000-12-06	FF	Patent granted
2001-06-14	KB	Patent renewed
2005-02-20	KB	Patent renewed
2009-07-20	KB	Patent renewed
2012-12-31	KB	Patent renewed
2015-07-30	EXP	Patent expired

Publication	Publication Date	Title
IL111991A (en)	2000-07-26	Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
IL129300A (en)	2003-07-06	Liquid pharmaceutical composition comprising an hiv protease inhibitor or a combination of hiv protease inhibitors in a pharmaceutically acceptable organic solvent
CA2189351A1 (en)	1995-11-23	Narcotic containing aerosol formulation
WO2002008217A3 (en)	2002-04-18	COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
GEP19991706B (en)	1999-08-05	(54) Heteroarylpiperidines, Pyrrolidines and Piperazines and Their Use As Antipsychotics and Analgetics
MY103802A (en)	1993-09-30	5-lipoxygenase inhibiting 4-(4-phenyl-1- piperazinyl) phenols.
CA2264901A1 (fr)	1998-03-12	Association inhibiteurs de no synthase et piegeurs des formes reactives de l'oxygene
ES2145254T3 (es)	2000-07-01	Formulaciones de aerosoles que contienen flunisolida.
CA2125888A1 (en)	1993-07-22	Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty
ATE257389T1 (de)	2004-01-15	Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren
ES2101449T3 (es)	1997-07-01	Inhibicion de la seborrea y el acne.
FI102475B1 (fi)	1998-12-15	Menetelmä farmaseuttisesti aktiivisten oktahydro- ja heksahydrobentso[f]kinolinonijohdannaisten valmistamiseksi
CA2259764A1 (en)	1999-08-02	Pharmaceutical compositions containing mupirocin
NZ237309A (en)	1993-02-25	1-(2-(4-morpholino)ethyl)-3-(arylcarbonyl)-indole derivatives and pharmaceutical compositions
NZ309151A (en)	2000-01-28	a 3-substituted cyano or carbamoyl pyrrole derivative and pharmaceutical composition
ES2161238T3 (es)	2001-12-01	Uso de 2-fenil-3-aroilbenzotiofenos para la preparacion de un medicamento para inhibir la angiogenesis y enfermedades angiogenicas.
ZA200302389B (en)	2004-04-23	Oral dosage self-emulsifying formulations of pyranone protease inhibitors.
ES2102026T3 (es)	1997-07-16	Derivados de bis-aril-carbinol puenteados, composiciones y metodos de uso.
MXPA03010672A (es)	2004-03-02	Composicion para el tratamiento regenerativo de enfermedades del cartilago.
CZ20011550A3 (cs)	2001-08-15	Opticky aktivní derivát pyridyl-4H-1,2,4-oxadiazinu, jeho použití při léčbě vaskulárních onemocnění a farmaceutické kompozice ho obsahující
UA37206C2 (uk)	2001-05-15	Фармацевтична композиція, яка містить алкілсульфонамід-агоніст 5нті- подібного рецептора для ректального введення
IL105475A (en)	1997-06-10	PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
MX9602984A (es)	1998-01-31	Composiciones farmaceuticas que contienen inhibidores de proteasa de vih.
AU9221898A (en)	1999-03-29	Pharmaceutical coating composition and method of use
AU6059094A (en)	1994-10-27	Active compound from a sponge